Abstract
Immune checkpoint inhibitors have revolutionised the management of NSCLC. However, the development of irAEs is associated with morbidity that can be lifelong and even fatal. While it has been suggested that human leukocyte antigen (HLA-I) homozygosity is associated with worse overall survival among NSCLC treated with single agent immunotherapy, its association with toxicity has not been examined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
